medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2020, Número S1

<< Anterior Siguiente >>

Ginecol Obstet Mex 2020; 88 (S1)


Complicaciones provocadas por los anticonceptivos orales combinados. Eventos tromboembólicos

Gómez-Tabares G

Idioma: Español
Referencias bibliográficas: 35
Paginas: 140-155
Archivo PDF: 270.89 Kb.


RESUMEN

Aunque la incidencia de trombosis venosa en mujeres de edad reproductiva es baja, su repercusión en usuarias de anticonceptivos orales es amplia. El consumo de anticonceptivos orales se estima en 100 millones de usuarias en todo el mundo. La evaluación de las diferentes combinaciones de anticonceptivos tiene participación importante al momento de prescribirlos. El objetivo de este estudio fue revisar las complicaciones provocadas por el consumo de anticonceptivos orales combinados. Se realizó una revisión sistemática de la bibliografía disponible en las bases PubMed, EMBASE y Scopus, en donde se buscaron los términos: “anticonceptivos orales combinados”, “dosis óptimas de anticonceptivos orales”, “complicaciones asociadas con anticonceptivos orales”, “tromboembolismo venoso”. Criterios de inclusión: artículos de casos o series que contuvieran los apartados de complicaciones asociadas con anticonceptivos orales combinados y reporte de al menos 75% de los datos clínicos establecidos. Todos los anticonceptivos orales combinados actuales confieren similar eficacia para prevenir el embarazo. Además de sus efectos anticonceptivos, las formulaciones con acetato de ciproterona o drospirenona se prescriben para el tratamiento de acné vulgar, seborrea e hirsutismo leve. El conocimiento de los riesgos y las complicaciones de los anticonceptivos orales combinados es decisivo. Es prioritario buscar la opción más segura en cada paciente, con l a finalidad de evitar el riesgo de trombosis venosa.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1998;877:1-89.

  2. Lidegaard O. Thrombotic diseases in young women and the influence of oral contraceptives. Am J Obstet Gynecol 1998;179:S62-S67.

  3. Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:I22-30. https://doi.org/10.1161/01. CIR.0000078464.82671.78

  4. Dahlman-Wright K, et al. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 2006;58:773- 81. https://doi.org/10.1124/pr.58.4.8

  5. Dickson RB, et al. 17 Alpha-ethinyl estradiol is more potent than estradiol in receptor interactions with isolated hepatic parenchymal cells. Endocrinology 1981;108:1511-8. https://doi.org/10.1210/endo-108-4-1511

  6. Fruzzetti F, et al. Review of clinical experience with estradiol in combined oral contraceptives. Contraception 2010;81:8- 5. https://doi.org/10.1016/j.contraception.2009.08.010.

  7. Mueck AO, et al. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 2011;76:531-9. https://doi. org/10.1016/j.steroids.2011.02.002.

  8. Mueck AO, et al. Why use of dienogest for the first contraceptive pill with estradiol? Gynecol Endocrinol 2009;26:109- 13. https://doi.org/10.3109/09513590903184167.

  9. Stanczyk FZ, et al. Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception 2013;87:706-727. https://doi.org/10.1016/j.contraception. 2012.12.011.

  10. Kemmeren JM, et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood 2004;103:927-33. https://doi.org/10.1182/ blood-2003-04-1285

  11. Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception 2003;67:173-85.

  12. Junge W, et al. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig 2011;31:573-84. https://doi.org/10.2165/11590220- 000000000-00000.

  13. Ågren UM, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care 2011;16:444-57. https://doi.org/10.3109/13625187 .2011.604450.

  14. Gaussem P, et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Thromb Haemost 2011;105:560-7. https://doi.org/10.1160/TH10-05-0327.

  15. Fruzzetti F. Hemostatic effects of smoking and oral contraceptive use. Am J Obstet Gynecol 1999;180:S369-74.

  16. Schumacher M, et al. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocr Rev 2007;28:387-439. https:// doi.org/10.1210/er.2006-0050

  17. Schindler AE, et al. Clasification and pharmacology of progestins. Maturitas 2008;61:171-80.

  18. Pomp ER, et al. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008;83:97-02. https://doi.org/10.1002/ ajh.21059

  19. Huerta C, et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007;167:935-943. 10.1001/archinte.167.9.935

  20. Naess IA, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-9. https://doi.org/10.1111/j.1538- 7836.2007.02450.x

  21. Heinemann LA, et al. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007;75:328-36. https://doi.org/10.1016/j. contraception.2006.12.018

  22. Jick H, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93.

  23. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre casecontrol study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1575-82.

  24. Løkkegaard E, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343:d6423. 10.1136/bmj.d6423.

  25. Lidegaard O, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890. https://doi.org/10.1136/bmj.b2890.

  26. Jick SS, et al. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;342:d2151. https://doi. org/10.1136/bmj.d2151.

  27. de Bastos M, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014;3(3):CD010813. https://doi.org/10.1002/14651858. CD010813.pub2.

  28. van Hylckama Vlieg A, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921. https://doi.org/10.1136/bmj.b2921.

  29. Weill A, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ 2016;353:i2002. https://doi.org/10.1136/bmj.i2002

  30. Mantha S, et al. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 2012;345:e4944. https://doi. org/10.1136/bmj.e4944

  31. Lidegaard Ø, et al. Venous thrombosis in users of nonoral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 2012;344:e2990. https://doi.org/10.1136/ bmj.e2990

  32. Arowojolu AO, et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2007;(3):CD004425. https://doi.org/10.1002/14651858. CD004425.pub3

  33. Gallo MF, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2008;(4):CD003987. https://doi.org/10.1002/14651858.CD003987.pub3.

  34. Lopez LM, et al. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2009;(2):CD006586. https://doi.org/10.1002/14651858. CD006586.pub3.

  35. Sitruk-Ware R. Pharmacologycal profile of progestins. Maturitas 2008;61:151-157.




2020     |     www.medigraphic.com